Valero V - Search Results

1

Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.

Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA. Andreopoulou E, et al. Among authors: valero v. Breast Cancer Res Treat. 2013 Oct;141(3):429-35. doi: 10.1007/s10549-013-2704-x. Epub 2013 Sep 26. Breast Cancer Res Treat. 2013. PMID: 24068539 Free PMC article. Clinical Trial.

2

Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.

Rivera E, Valero V, Esteva FJ, Syrewicz L, Cristofanilli M, Rahman Z, Booser DJ, Hortobagyi GN. Rivera E, et al. Among authors: valero v. Cancer Chemother Pharmacol. 2002 Apr;49(4):299-302. doi: 10.1007/s00280-001-0405-3. Epub 2001 Dec 18. Cancer Chemother Pharmacol. 2002. PMID: 11914909

3

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Esteva FJ, et al. Among authors: valero v. J Clin Oncol. 2002 Apr 1;20(7):1800-8. doi: 10.1200/JCO.2002.07.058. J Clin Oncol. 2002. PMID: 11919237 Clinical Trial.

4

Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.

Rivera E, Valero V, Cristofanilli M, Frye DK, Booser DJ, Rosales MM, Hortobagyi GN. Rivera E, et al. Among authors: valero v. Cancer. 2002 May 1;94(9):2321-6. doi: 10.1002/cncr.10488. Cancer. 2002. PMID: 12015755 Free article. Clinical Trial.

5

A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.

Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. Giordano SH, et al. Among authors: valero v. Clin Cancer Res. 2002 Nov;8(11):3360-8. Clin Cancer Res. 2002. PMID: 12429622 Clinical Trial.

6

Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy.

Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Buchholz TA, et al. Among authors: valero v. Cancer J. 2003 Jan-Feb;9(1):33-41. doi: 10.1097/00130404-200301000-00007. Cancer J. 2003. PMID: 12602766

7

A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.

Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. Assikis V, et al. Among authors: valero v. Cancer. 2003 Jun 1;97(11):2716-23. doi: 10.1002/cncr.11396. Cancer. 2003. PMID: 12767083 Free article. Clinical Trial.

8

Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Pusztai L, et al. Among authors: valero v. Clin Cancer Res. 2003 Jul;9(7):2406-15. Clin Cancer Res. 2003. PMID: 12855612

9

A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.

Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. Trent JC, et al. Among authors: valero v. Clin Cancer Res. 2003 Jul;9(7):2426-34. Clin Cancer Res. 2003. PMID: 12855614 Clinical Trial.

10

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.

Esteva FJ, Rivera E, Cristofanilli M, Valero V, Royce M, Duggal A, Colucci P, DeJager R, Hortobagyi GN. Esteva FJ, et al. Among authors: valero v. Cancer. 2003 Sep 1;98(5):900-7. doi: 10.1002/cncr.11557. Cancer. 2003. PMID: 12942555 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

497 results

Search Page

Filters